Monitoring of patients on long-term glucocorticoid therapy

Medicine (United States)

Volumn 94, Issue 15, 2015, Pages

  Fardet, Laurence ^a,b,c   Petersen, Irene ^a   Nazareth, Irwin ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b HENRI MONDOR HOSPITAL   (France)

^c UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; CHOLESTEROL; DEFLAZACORT; DEXAMETHASONE; GLUCOCORTICOID; GLUCOSE; INFLUENZA VACCINE; LIPID; METHYLPREDNISOLONE; PNEUMOCOCCUS VACCINE; POTASSIUM; PREDNISOLONE; PREDNISONE; TRIACYLGLYCEROL; TRIAMCINOLONE; GLUCOSE BLOOD LEVEL; VACCINE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; BODY WEIGHT; CLINICAL ASSESSMENT; COMORBIDITY; CORTICOSTEROID THERAPY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG EXPOSURE; DUAL ENERGY X RAY ABSORPTIOMETRY; EYE DISEASE; EYE EXAMINATION; FEMALE; FOLLOW UP; GENERAL PRACTICE; HUMAN; INFLUENZA; INFLUENZA VACCINATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PATIENT REFERRAL; POPULATION BASED CASE CONTROL STUDY; POTASSIUM BLOOD LEVEL; PRESCRIPTION; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; SYSTOLIC BLOOD PRESSURE; BLOOD; BLOOD PRESSURE; COHORT ANALYSIS; DRUG MONITORING; GLUCOSE BLOOD LEVEL; MIDDLE AGED; MORPHOMETRICS; STATISTICS AND NUMERICAL DATA; TIME; VISUAL SYSTEM EXAMINATION;

AGED; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHTS AND MEASURES; COHORT STUDIES; DIAGNOSTIC TECHNIQUES, OPHTHALMOLOGICAL; DRUG MONITORING; FEMALE; GLUCOCORTICOIDS; HUMANS; LIPIDS; MALE; MIDDLE AGED; POTASSIUM; TIME FACTORS; VACCINES;

EID: 84929494018     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000647     Document Type: Article

References (34)

1. Fardet L, Petersen I, Nazareth I. Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years. Rheumatol Oxf Engl. 2011;50:1982-1990.
2. Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids in the United Kingdom. QJM. 2000;93:105-111.
3. Fardet L, Flahault A, Kettaneh A, et al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion. Br J Dermatol. 2007;157:142-148.
4. Perdoncini-Roux A, Blanchon T, Hanslik T, et al. [Description of French general practitioners' practices regarding long term systemic corticosteroid therapy-associated measures]. Rev Prat. 2009;59: 19-24.
5. Fardet L, Hanslik T, Blanchon T, et al. [Long-term systemic corticosteroid-therapy associated measures: description of the French internal medicine physicians' practices]. Rev Méd Interne. 2008;29:975-980.
6. Duru N, van der Goes MC, Jacobs JWG, et al. EULAR evidencebased and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2013;72:1905-1913.
7. Hoes JN, Jacobs JWG, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007;66:1560-1567.
8. Van der Goes MC, Jacobs JWG, Boers M, et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis. 2010;69:1913-1919.
9. Lis Y, Mann RD. The VAMP Research multi-purpose database in the UK. J Clin Epidemiol. 1995;48:431-443.
10. Blak BT, Thompson M, Dattani H, et al. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care. 2011;19:251-255.
11. Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care. 2004;12:171-177.
12. Ruigómez A, Martn-Merino E, Rodŕguez LAG. Validation of ischemic cerebrovascular diagnoses in the health improvement network (THIN). Pharmacoepidemiol Drug Saf. 2010;19:579-585.
13. Lewis JD, Schinnar R, Bilker WB, et al. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf. 2007;16:393-401.
14. Lewis JD, Bilker WB, Weinstein RB, et al. The relationship between time since registration and measured incidence rates in the General Practice Research Database. Pharmacoepidemiol Drug Saf. 2005;14:443-451.
15. Chast F. [History of corticotherapy]. Rev Méd Interne. 2013;34:258-263.
16. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 2010;62:1515-1526.
17. http://www.has-sante.fr/portail/upload/docs/application/pdf/osteoporo se-synthese.pdf. Accessed January 2015.
18. https://www.rcplondon.ac.uk/sites/default/files/documents/glucocorti coid-induced-osteoporosis-concise.pdf. Accessed January 2015.
19. http://www.cdc.gov/mmwr/preview/mmwrhtml/00023141.htm. Accessed January 2015.
20. http://www.nhs.uk/Conditions/vaccinations/Pages/flu-influenza-vacci ne.aspx. Accessed January 2015.
21. http://www.nhs.uk/Conditions/vaccinations/Pages/when-is-pneumo coccal-vaccine-needed.aspx. Accessed January 2015.
22. http://www.sante.gouv.fr/IMG/pdf/Calendrier-vaccinal-detail le-2013-ministere-Affaires-sociales-et-Sante-pdf.pdf. Accessed January 2015.
23. Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med. 1994;236:619-632.
24. Blackburn D, Hux J, Mamdani M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Intern Med. 2002;17:717-720.
25. Souverein PC, Berard A, Van Staa TP, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart Br Card Soc. 2004;90:859-865.
26. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141:764-770.
27. Fardet L, Cabane J, Kettaneh A, et al. Corticosteroid-induced lipodystrophy is associated with features of the metabolic syndrome. Rheumatol Oxf Engl. 2007;46:1102-1106.
28. Arena C, Morin A-S, Blanchon T, et al. Impact of glucocorticoidinduced adverse events on adherence in patients receiving long-term systemic glucocorticoid therapy. Br J Dermatol. 2010;163:832-837.
29. Fardet L, Petersen I, Nazareth I. Risk of cardiovascular events in people prescribed glucocorticoids with iatrogenic Cushing's syndrome: cohort study. BMJ. 2012;345:e4928.
30. Overman RA, Yeh J-Y, Deal CL. Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res. 2013;65:294-298.
31. Fardet L, Cabane J, Lebbé C, et al. Incidence and risk factors for corticosteroid-induced lipodystrophy: a prospective study. J Am Acad Dermatol. 2007;57:604-609.
32. Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int. 2005;16:229-238.
33. http://www.rcophth.ac.uk/page.aspsection=293sectionTitle=Ophthalmic+ Services+Guidance. 2014. Accessed August 2014.
34. Elixhauser A, Owens P. Adverse Drug Events in U.S. Hospitals, 2004: Statistical Brief #29. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Health Care Policy and Research (US); 2006 [cited 2014 Aug 4]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK63500/. Accessed August 2014.